Dr Christophe Willekens

Spécialité

Hématologue, expert myélome et leucémie

Hôpital

Gustave Roussy (Villejuif)

Derniers articles

• Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. (17 avr. 2025)
• Venetoclax-proteasome inhibitor-dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm. (25 févr. 2025)
• Relevance, Risks, and Benefits of Early-Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023. (1 janv. 2025)
• Circulating Proteins Associated with Anti-IL6 Receptor Therapeutic Resistance in the Sera of Patients with Severe COVID-19. (1 nov. 2024)
• CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemia. (17 sept. 2024)